Biofarm (stock symbol BIO), one of the most important drug manufacturers in Romania, announces increased production of paracetamol-based medicines for the treatment of fever and pain in children to meet increased market demand. We are in the middle of the children's respiratory season and paracetamol-based medicines are very hard to find or are missing from pharmacies. Therefore, we have mobilised and decided to significantly increase production of Bioflu Baby, a paracetamol-based syrup for treating fever and pain in children. Biofarm has an extensive portfolio of products for children colds and flu, and our two manufacturing facilities have the capacity to adapt quickly to any market need, said Catalin Vicol, Biofarm CEO. Biofarm has always focused on aligning itself with market requirements and patient needs, being a company always oriented towards innovation and facilitating access to modern treatment solutions. In the first ten months of 2022, Biofarm ranked 3rd in the Consumer Healthcare (CHC) segment in terms of number of units sold. The Cold Flu therapeutic area saw the highest growth in the Consumer Healthcare (CHC) category, with products such as Bioflu, Carmol, Bixtonim Xylo and Septosol recording double-digit growth. Biofarm currently has two drug factories in Bucharest and a product testing and development unit, and its portfolio of over 200 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory , ORL, cardiovascular ,circulatory, nervous system). With more than 20 representative brands, Biofarm is the market leader in terms of volumes in the reference categories of nine of its brands: Colebil, Triferment, Carbocit, Sennalax, Bixtonim, Carmol, Biofen, Nervocalmin and Cavit. About Biofarm Biofarm® is one of the first Romanian drug and food supplements producers. For 100 years, Biofarm® has stood alongside Romanian specialists in the race to discover the best solutions for maintaining people health. Biofarm® is currently one of the top 10 existing producers on the pharmaceutical market in Romania, a very dynamic and competitive market. Biofarm® has a competitive product portfolio, covering 65 therapeutic areas, and is continuously investing in media, commercial and marketing campaigns to promote its products.
The latest study conducted by Coface Romania revealed that 7,274 new insolvency proceedings were opened in 2024, compared to 6,650 in 2023, marking a 9.38% increase. Among companies with a turnover above EUR 5 million, there was a 75% rise in insolvencies last year. Denied payment instruments have increased both in value (+30%) and number […]
The Parliament has voted in favor of the new bill permitting the Romanian Army to shoot down drones that fly unauthorized in Romania’s airspace. The legislation now moves to acting president Ilie Bolojan for promulgation. Last week, the Chamber of Deputies approved the law as the first chamber to be consulted, followed by final approval […]
Garanti BBVA has granted a EUR 7.5 million loan to MG Tec Industry SRL, the leading Romanian producer of paper tissues. The financing benefits from a state guarantee issued by Exim Banca Românească, covering up to 75% of the loan value. Garanti BBVA and MG TEC Industry share a commitment to sustainability, with MG Tec […]
One United Properties (BVB: ONE), Romania’s leading green developer of residential,...
Controversial social media influencer Andrew Tate and his brother Tristan, who are being investigated on several charges related to human trafficking and other offenses, left Romania in the early hours of Thursday, February 27, according to media reports. They are reportedly heading to the US by private jet. According to
One United Properties (BVB: ONE), Romania’s leading green developer of residential, mixed-use, and office real estate, recorded a preliminary turnover of 285.5 million euros in 2024, gross profit of 88.6 million euros, while the net profit for the year stood at 76.7 million euros. “Over the past five years, One United Properties has transformed from […]
